Fund moves
2.0%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LENZ · NASDAQ · Biological Products, (No Diagnostic Substances)
Lenz Therapeutics (LENZ) · oqro.io/stocks/LENZ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.97−0.375 (−11.23%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Lenz Therapeutics was filed in the last 90 days. The latest on record was on Mar 30, 2026.
Since 2021, Lenz Therapeutics insiders reported 30 open-market purchases and 33 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2026.
In the last 90 days, 1 insider of Lenz Therapeutics (LENZ) reported 3 open-market sales worth $9.13M in total on SEC Form 4. The largest seller by value was RA CAPITAL MANAGEMENT, with $9.13M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Lenz Therapeutics (LENZ) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−89.3% (−$24.76) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $27.72 on Nov 20, 2025 to $2.97 on Nov 20, 2026 (−89.3%). Disclosed in this range: 6 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Solana Beach, Ca.
Last 12 months
−88.2%
Market value
$105M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 7.07M shares sold short (22.5% of shares outstanding), −22.3% vs the previous count, 5.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$19.1M
Year ended Dec 31, 2025
Net income, fiscal 2025
−$82.1M
A loss for the year
Shares outstanding
31.4M
As of Oct 28, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Traded Oct 29, 2026 · largest single transaction ~$7.26MNot reported under a pre-arranged trading plan
Oct 29, 2026~$7.26M · 2.16M sh @ $3.36
DetailsOfficial recordOct 29, 2026~$1.52M · 452K sh @ $3.36
DetailsOfficial recordFund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by software from the filings listed below · Nov 13, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up freeAgainst the S&P 500 over the year
Since Nov 17, 2025, LENZ is down 87.0% and the index fund is up 7.5%: 95 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much LENZ moves
Beta 2.0 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 248 trading days (1 = in step with it).
BML Investment Partners, L.P.
13G · passive · Crossed 5% · 2.11M shares · filed Nov 4, 2026
BlackRock Portfolio Management LLC
13G · passive · Crossed 5% · 1.65M shares · filed Oct 27, 2026
Recent moves
FMR LLC fell below 5% (2%) · Schedule 13G, 2026
BML Investment Partners, L.P. went above 5%, with 6.7% · Schedule 13G, 2026
RA Capital Management, L.P. fell below 5% (0.2%) · Schedule 13D, 2026
BlackRock Portfolio Management LLC went above 5%, with 5.2% · Schedule 13G, 2026
Millennium Management LLC fell below 5% (3.7%) · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Top officer leaving
“Resignation of President, Chief Executive Officer and Director On October 28, 2026, the Company announced that Evert Schimmelpennink, the Company’s President and Chief Executive Officer (“CEO”), will transition from his roles as President and CEO effective December 1, 2026 (the “CEO Transition Date”), with Daniel Chevallard, the Company’s current Chief Financial Officer, to succeed him as Interim”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Lenz Therapeutics reported 30 open-market purchases and 33 sales since 2021; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $366K3×3 trades | $9.13M3×3 trades |
| 2025 | $289K3×3 trades | $56.5M30×30 trades |
| 2024 | $15.6M4×4 trades | — |
| 2022 | $3.74M7×7 trades | — |
| 2021 | $19.6M13×13 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Revenue
$3.38M
−72.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$128M
This quarter −$22.3M, a year earlier −$9.03M
Net debt
—
Debt —, cash $30.6M, at Sep 30, 2026
Net income, last 12 months
−$140M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 28, 2026.
Revenue and earnings history, 6 fiscal yearsEarnings dates and the stock's moves
Who holds it
Things to keep in mind
Records
Last results
Oct 28, 2026
Within the 30 days after it, until Nov 27, 2026
Next results, expected
Not announced
Purchases after results
48%
12 of 25 insider purchases since 2021 came within 30 days after a results announcement
From Lenz Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Lenz Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 24, 2026. Read the filing
$0 the year before
$0 the year before
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
We are a commercial pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States (“U.S.”). We are commercializing VIZZ in the U.S. and continue to establish licensing partnerships internationally to provide access to VIZZ globally. We believe that a once-daily pharmacological eye drop that can effectively and safely improve near vision throughout the full workday, without the need for reading glasses, is a highly attractive commercial product with an estimated U.S. market opportunity in excess of $3 billion.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 24, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Fails to deliver: 475K shares (about $1.66M) were not delivered on time for settlement on Oct 30, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 44.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (24.0% on ATS, 20.2% with other brokers), close to its 26-week average of 43.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (14.8%), INSTINCT X (12.3%), UBS ATS (11.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 24, 2026, compared with the one filed Mar 19, 2025. Read the filing
From time to time, we may be subject to legal proceedings and claims arising in the ordinary course of our business. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Source: SEC EDGAR, Form 10-K filed Mar 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.